EMA Receives Application for Conditional Marketing Authorisation of COVID-19 mRNA Vaccine BNT162b2

4 December 2020 – The assessment of BNT162b2, a COVID-19 mRNA vaccine developed by BioNTech and Pfizer, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued within weeks.

For further information, see here.